Close

We are using cookies to give you the best experience on our site. Cookies are files stored in your browser and are used by most websites to help personalise your web experience.

By continuing to use our website without changing the settings, you are agreeing to our use of cookies.

Find out more
For more information, go to www.arthritisresearchuk.org

The benefits and risks of treating joint pain in older people with opioid medications

Issue 32 Synovium (Spring 2011)

Download this issue (opens in new window)(159.9 KB)

A systematic review published in the Journal of the American Geriatrics Society1 looked at evidence with respect to the ‘efficacy, safety, and abuse and misuse potential’ of opioid drugs in older people (>60 years) with non-cancer pain. 43 studies were identified as suitable for inclusion and in these 70% of patients were treated for osteoarthritis. The studies were rather short (median duration 4 weeks) with only 5 lasting longer than 12 weeks.

Significant (though modest) reductions in pain and disability and non-significant improvements in sleep and physical quality of life (as measured by SF36) were found by meta-analysis of 18 studies comparing opioid with placebo. Adverse events were common, however, and 1 in 4 patients discontinued the active treatment. Constipation was the commonest adverse event, with nausea, dizziness and somnolence close behind. Misuse or abuse of opioids was found to be uncommon in older patients. High-potency opioids were not found to be more effective in relieving pain than weak or moderate-strength opioids. Long-acting preparations were found to be more effective than shorter-acting preparations.

The short duration of the studies is a particular problem. Patients with osteoarthritis are highly likely to need long-term pain control. Benefits of treatment tend to occur earlier in treatment and adverse effects later – sometimes much later. The authors conclude that it is therefore difficult to make meaningful risk-benefit analyses, and this is congruent with an earlier Cochrane Review2 which gave both a number needed to treat and a number needed to harm of 6 for opioid medications. Another study3 suggesting that long-term use of opioid medication is problematic in older people examined the healthcare records of Medicare beneficiaries in the USA. Fracture events were correlated with prescription of opioids and NSAIDs. 38 fracture events were documented in 4874 NSAID users and 587 events in 12,436 opioid users. The hazard ratio was 4.9 for opioid users compared with NSAID users. Risk was higher in users of short-acting opioids – HR 5.1 as opposed to 2.6 with long-acting preparations. These findings offer no great encouragement to prescribe opioids for older patients with joint pain as an alternative to NSAIDs, and underline the difficulty of prescribing safe and effective pain-relieving treatments for this patient group. So would these patients’ outcomes be any better if they did choose to consult their doctor?!

Synovium archives

Browse previous issues of Synovium (all issues available as downloadable PDFs)
For more information, go to www.arthritisresearchuk.org.
Arthritis Research UK fund research into the cause, treatment and cure of arthritis. You can support Arthritis Research UK by volunteering, donating or visiting our shops.